LATS1 and neoplasm: It was reported previously that YAP activation unexpectedly enhanced anti-tumor immunity [24]; it is possible that LATS1/2 deletion in mouse tumor cell models (B16, SCC7, and 4T1) in that study did not upregulate the immune checkpoints.